Replies to post #227936 on Biotech Values

[biocqr]

The +5% response to the phase-3 migraine data is surprisingly tepid.

Are you referring to the 5.1% difference of pain freedom pts at 2-24 hrs between AXS-07 and rizatriptan of 16.1% vs 11.2%? Why is it one measurement and not two measurements at 2 and 24 hrs?

Superiority of AXS-07 to rizatriptan and MoSEIC™ meloxicam (component contribution) was established as specified in the SPA, by demonstration of a greater percentage of AXS-07 patients achieving sustained pain freedom from 2 to 24 hours after dosing, compared to rizatriptan and MoSEIC™ meloxicam, as well as to placebo (16.1%, 11.2%, 8.8% and 5.3%, respectively; p=0.038, p=0.001, and p<0.001, respectively versus AXS-07).

[kris_kade]

Agree, Dew. I am surprised too. However the stock is getting more & more de-risked even at these levels and I have no worry holding all into 2020.

Waiting for TRD and AA. 3 of my 5 bets are a win (for me) so far. :)